Cue Biopharma Inc. (CUE) exceeded earnings expectations in the second quarter of 2024, reporting a smaller-than-expected loss and exceeding revenue estimates. The company’s strong performance and positive earnings outlook have earned it a Zacks Rank #2 (Buy), indicating potential for outperformance in the near future. This comes despite the stock’s decline earlier this year. Meanwhile, the Medical – Biomedical and Genetics industry remains strong, suggesting continued positive momentum for Cue Biopharma.